PRECISION MEDICINE DIAGNOSTICS MARKET ANALYSIS

Name: Precision Medicine Diagnostics Market News
Creator: Coherent Market Insights
License: https://www.coherentmarketinsights.com/privacy-policy

Precision Medicine Diagnostics Market, by Technology (Bioinformatics, Gene Sequencing, Drug Discovery, Precision Molecular Diagnostics, and Big Data Analytics), by application (Oncology, CNS, Hematology, Respiratory, Immunology, and Others), and by Region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

To Be Published : Sep 2024
Code : CMI2422
Formats :
Excel and PDF
Industry : Clinical Diagnostic

Market News

Key Development

In May 2019, QIAGEN N.V., launched PIK3CA RGQ PCR biomarker to enhance precision medicine in breast cancer patient.
In February 2019, ICON plc., a global leader in drug development solution and service acquired Molecular MD for the development and commercialization of precision medicines in oncology.
In 2018, Syapse, Inc., a leading precision medicine company entered into collaboration with Roche to make precision medicine for cancer patients.
In January 2018, Syapse collaborated with Roche in order to advance precision medicine in oncology. Also, this partnership focuses on clinical delivery and product development for introducing precision medicine.
In 2018, Konica Minolta Inc., launched Konica Minolta precision medicine in japan.

PRECISION MEDICINE DIAGNOSTICS MARKET ANALYSIS

Market News

Precision Medicine Diagnostics Market Report Snapshots

EXISTING CLIENTELE